INVA — Innoviva, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1080014 ·
Last close
$18.30
Market Cap
$1.30B
52W High
$25.15
52W Low
$18.28
ADV30
801,024
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 106,120,000 | 84,382,000 | 42,153,000 | -73,888,000 | 1,537,926,000 | 581,394,000 | 400,408,000 |
| Jun 2026 | 119,591,000 | 90,616,000 | 50,855,000 | -83,420,000 | 1,702,727,000 | 570,388,000 | 469,465,000 |
| Mar 2026 | 97,994,000 | 82,387,000 | 38,154,000 | 186,595,000 | 1,836,587,000 | 603,085,000 | 494,932,000 |
| Dec 2025 | 114,613,000 | 101,944,000 | 38,988,000 | 164,153,000 | 1,635,165,000 | 550,941,000 | 462,324,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$183,465,000
Investing CF
$-49,000
Financing CF
$-78,535,000
CapEx
$-955,000
Dividends Paid
—
Buybacks
$-82,257,000
EPS Diluted TTM
$1.99
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$298,655,000
Inventory
$42,838,000
Receivables
$102,130,000
ST Investments
$8,667,000
EBIT TTM
$243,659,000
Pretax Income TTM
$223,969,000
Interest Exp TTM
$19,690,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$438,318,016
EBITDA
$199,807,008
Free Cash Flow
$121,162,376
Enterprise Value
$1,098,630,272
Total Cash
$590,060,992
Total Debt
$331,035,008
Shares Out
71,081,477
Trailing EPS
$2.35
Book Value
$15.90
ROE
18.0%
ROA
7.3%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 411,328,000 | 163,745,000 | 271,165,000 | 1,635,165,000 | 462,324,000 | 1,172,841,000 | 196,930,000 |
| Dec 2024 | 358,711,000 | 166,867,000 | 23,392,000 | 1,301,060,000 | 609,901,000 | 691,159,000 | 188,690,000 |
| Dec 2023 | 310,463,000 | 113,885,000 | 179,722,000 | 1,243,507,000 | 568,552,000 | 674,955,000 | 141,064,000 |
| Dec 2022 | 331,339,000 | 206,995,000 | 213,921,000 | 1,231,497,000 | 665,709,000 | 565,788,000 | 201,726,000 |
TTM Snapshot
Revenues TTM
$439,998,000
NetIncome TTM
$357,236,000
OpCashFlow TTM
—
Assets (Latest)
$1,702,727,000
Forward EPS
$2.21
Max Pain — expiry 2026-12-18
max pain strike: $22.50 · spot: $18.40 · call oi: 1,008 · put oi: 244
Expected Move to 2026-12-18:
±$3.95
(21.47%) —
implied range
$14.45 –
$22.35
· ATM straddle on $17.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GPCR | Structure Therapeutics Inc. | $1.30B | $18.17 | — |
| LBRX | LB PHARMACEUTICALS INC | $1.30B | $40.30 | — |
| MNKD | MANNKIND CORP | $1.31B | $4.07 | — |
| MLYS | Mineralys Therapeutics, Inc. | $1.28B | $14.48 | — |
| OCUL | OCULAR THERAPEUTIX, INC | $1.32B | $6.02 | — |
News headlines (Yahoo Finance, 1h cache)
Is Quarterly Loss Altering The Investment Case For Innoviva Stock (INVA)?
2026-11-16 23:23 · Yahoo
Is Innoviva (INVA) Stock Undervalued Right Now?
2026-11-10 13:40 · Yahoo
INVA or MRK: Which Is the Better Value Stock Right Now?
2026-11-09 15:40 · Yahoo
Innoviva (INVA) Tops Q3 Earnings Estimates
2026-11-04 23:45 · Yahoo
Innoviva: Q3 Earnings Snapshot
2026-11-04 23:05 · Yahoo
Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
2026-10-19 12:00 · Yahoo
Do Options Traders Know Something About Innoviva Stock We Don't?
2026-10-12 14:11 · Yahoo
Is Innoviva (INVA) Undervalued As Zacks Flags Its Value Appeal?
2026-10-08 19:19 · Yahoo
INVA vs. MRK: Which Stock Is the Better Value Option?
2026-10-08 14:40 · Yahoo
Should Value Investors Buy Innoviva (INVA) Stock?
2026-10-08 12:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.